368 related articles for article (PubMed ID: 36695751)
1. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis.
Barati Sedeh F; Michaelsdóttir TE; Henning MAS; Jemec GBE; Ibler KS
Acta Derm Venereol; 2023 Jan; 103():adv00855. PubMed ID: 36695751
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
[TBL] [Abstract][Full Text] [Related]
3. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
Papierzewska M; Waśkiel-Burnat A; Rudnicka L
Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
[TBL] [Abstract][Full Text] [Related]
4. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
[TBL] [Abstract][Full Text] [Related]
8. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
9. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of JAK inhibitors in the treatment of alopecia areata in children: a systematic review and meta-analysis.
Chen Y; Zhu H; Shen Y; Zhu Y; Sun J; Dai Y; Song X
J Dermatolog Treat; 2022 Dec; 33(8):3143-3149. PubMed ID: 36214579
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata: A Pooled Analysis of the BRAVE-AA1 and BRAVE-AA2 Trials.
Ko JM; Mayo TT; Bergfeld WF; Dutronc Y; Yu G; Ball SG; Somani N; Craiglow BG
JAMA Dermatol; 2023 Sep; 159(9):970-976. PubMed ID: 37556146
[TBL] [Abstract][Full Text] [Related]
13. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
15. Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: A multicentric study.
Lobato-Berezo A; March-Rodríguez A; Grimalt R; Rodríguez-Lomba E; Setó-Torrent N; Pujol RM; Ruiz-Villaverde R
Dermatol Ther; 2022 Nov; 35(11):e15806. PubMed ID: 36070222
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib as the first systemic treatment for severe alopecia areata.
Kincaid CM; Arnold JD; Mesinkovska NA
Expert Rev Clin Immunol; 2023 Jun; 19(6):565-573. PubMed ID: 37042112
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients.
Mao MQ; Ding YX; Jing J; Tang ZW; Miao YJ; Yang XS; Chen YH; Chen SZ; Wu XJ; Lu ZF
Front Immunol; 2023; 14():1195858. PubMed ID: 37334349
[TBL] [Abstract][Full Text] [Related]
19. Baricitinib: A Review in Severe Alopecia Areata.
Fung S; Shirley M
Am J Clin Dermatol; 2023 Jul; 24(4):661-668. PubMed ID: 37326792
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
King B; Mesinkovska N; Mirmirani P; Bruce S; Kempers S; Guttman-Yassky E; Roberts JL; McMichael A; Colavincenzo M; Hamilton C; Braman V; Cassella JV
J Am Acad Dermatol; 2022 Aug; 87(2):306-313. PubMed ID: 35364216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
